Ocugen (OCGN) Total Debt (2014 - 2026)
Ocugen's (OCGN) quarterly Total Debt came in at $29.2 million in Q1 2026, up 5.51% YoY from $27.7 million in Q1 2025, and up 1.4% on a QoQ basis from $28.8 million in Q4 2025.
Ocugen (OCGN) Total Debt (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Total Debt data on file, last reported at $29.2 million in Q1 2026.
- Quarterly Total Debt rose 5.51% year-over-year to $29.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.2 million (up 5.51% YoY) and the FY2025 annual result came in at $28.8 million, changed 0.42% from the prior year.
- Total Debt climbed to $29.2 million in Q1 2026, from $28.8 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $29.2 million in Q1 2026 to a low of $1.7 million in Q1 2022.
- A 5-year average of $11.6 million and a median of $2.8 million in 2024 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2022 — Total Debt declined 29.35% — and 2024, when it soared 923.96%.
- Tracing OCGN's Total Debt over 5 years: stood at $2.3 million in 2022, then rose by 22.32% to $2.8 million in 2023, then soared by 923.96% to $28.7 million in 2024, then rose by 0.42% to $28.8 million in 2025, then climbed by 1.4% to $29.2 million in 2026.
- The last three Total Debt figures came in at $29.2 million (Q1 2026), $28.8 million (Q4 2025), and $28.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 1.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.75 Mn |
| Mar 31, 2026 | 29.19 Mn |
| Dec 31, 2025 | 28.79 Mn |
| Sep 30, 2025 | 28.40 Mn |
| Jun 30, 2025 | 28.03 Mn |
| Mar 31, 2025 | 27.67 Mn |
| Dec 31, 2024 | 28.67 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | 2.77 Mn |
| Jun 30, 2023 | 2.74 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | 2.29 Mn |
| Sep 30, 2022 | 2.27 Mn |
| Jun 30, 2022 | 1.75 Mn |
| Mar 31, 2022 | 1.73 Mn |
| Dec 31, 2021 | 1.71 Mn |
| Sep 30, 2021 | 1.69 Mn |